8-K: Quoin Pharmaceuticals Receives Nasdaq Extension to Regain Compliance with Minimum Bid Price Rule

Quoin Pharmaceuticals has been granted an additional 180 days, until April 28, 2025, by Nasdaq to regain compliance with the minimum bid price requirement.

Summary

• Quoin Pharmaceuticals previously received a notice from Nasdaq on April 29, 2024, stating they were not compliant with the $1.00 minimum bid price requirement.
• The company was initially given 180 days, until October 28, 2024, to regain compliance.
• On October 16, 2024, Quoin requested an additional 180-day grace period.
• Nasdaq granted this request on October 29, 2024, extending the deadline to April 28, 2025.
• The extension was granted because Quoin met the continued listing requirements for market value of publicly held shares and other initial listing standards, except for the minimum bid price.
• Quoin also indicated its intention to cure the deficiency, potentially through a reverse stock split.
• The company's stock will continue to trade on the Nasdaq Capital Market under the symbol QNRX.
• To regain compliance, the closing bid price of Quoin's ADSs must be at or above $1.00 for a minimum of ten consecutive business days during the extended period.
• If compliance is not achieved by April 28, 2025, Nasdaq may delist the company's securities, which Quoin could appeal.

Sentiment

Score: 4

Explanation: The document highlights a significant compliance issue with Nasdaq, which is a negative signal. While an extension was granted, the underlying problem of a low stock price remains, and the risk of delisting is still present. The sentiment is therefore negative.

Positives

• Nasdaq has granted Quoin an additional 180 days to regain compliance, providing more time to address the minimum bid price issue.
• The company continues to meet other listing requirements, indicating underlying strength.
• Quoin has a clear path to regain compliance by achieving a $1.00 minimum bid price for ten consecutive days.
• The company has the option to implement a reverse stock split if necessary to meet the minimum bid price requirement.

Negatives

• Quoin is not currently compliant with Nasdaq's minimum bid price requirement, which is a significant concern.
• The company's stock price has been below $1.00, triggering the initial non-compliance notice.
• There is a risk of delisting if the company fails to regain compliance by April 28, 2025.

Risks

• The company's stock price may not reach or sustain the $1.00 minimum bid price for ten consecutive days.
• A reverse stock split, while a potential solution, could negatively impact shareholder value.
• Delisting from Nasdaq would significantly impact the company's access to capital and investor confidence.
• The company may face challenges in regaining investor confidence if the stock price remains low.

Future Outlook

Quoin intends to actively monitor its ADS bid price and consider all available options, including a potential reverse stock split, to regain compliance with Nasdaq listing requirements.

Management Comments

• The company intends to actively monitor the bid price of its ADSs and will consider available options to regain compliance with Nasdaq's listing requirements.

Industry Context

Many small-cap biotech companies face challenges in maintaining their stock price above the minimum bid price required by exchanges like Nasdaq, especially during periods of market volatility or when facing clinical trial setbacks. This situation is not unique to Quoin, and the company's response is typical of companies in similar circumstances.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining minimum bid prices on exchanges like Nasdaq.
• A reverse stock split is a common strategy used by companies in this situation to increase their share price.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have also faced similar delisting risks and have taken steps to regain compliance.
• The 180-day extension granted to Quoin is a standard procedure by Nasdaq for companies facing minimum bid price deficiencies.

Stakeholder Impact

• Shareholders face the risk of further stock price decline and potential delisting.
• Employees may experience uncertainty due to the company's financial challenges.
• Creditors may be concerned about the company's ability to meet its obligations if delisted.

Next Steps

• Quoin will actively monitor the bid price of its ADSs.
• The company will consider available options to regain compliance with Nasdaq's listing requirements, including a potential reverse stock split.
• Quoin must achieve a closing bid price of $1.00 or more for at least ten consecutive business days before April 28, 2025, to regain compliance.

Key Dates

Keywords

Nasdaq, minimum bid price, compliance, delisting, reverse stock split, QNRX, listing requirements, ADS, extension